Colorectal Cancer Debate: First Line BRAF V600E - Targeted Triplet

Earn CME for related programs:
naccme.com/oln
In this presentation from the '2019 Great Debates & Updates in Gastrointestinal Malignancies' in New York', Dr. Pashtoon M. Kasi argues in favor of utilizing a targeted, three-drug combination for the first-line treatment of BRAF V600E colorectal cancer.
© 2019 Imedex, an HMP Company